WHO WE ARE
SEE THE STORY
Difference Made Together
HLB LifeScience Bio Business
- Tegatrabeten (BC-2059)
- Tegatrabeten (BC-2059) is a new chemotherapeutic agent that blocks the Wnt / beta-catenin signaling pathway in cancer stem cells. It has few side effects and is independent of the mutation of beta-catenin. So it is an effective anti-cancer clinical drug for various cancers.
- SP-2577 is highly bioavailable, irreversible and highly selective Lysine Specific Demethylase 1 (LSD1) inhibitor is used for various cancers. (prostate cancer, breast cancer, Small cell lung cancer, bladder cancer,
- Core Technology
- Driving innovation across oncology,
immunology, neuroscience and more.
- Advancing medicines with strong clinical
performance in areas of great need.
- Research Achievement
- Work with us to turn world-class research
into life-changing results.